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Abstract
AIM: To determine the relationship of pulmonary ab-
normalities and bowel disease activity in inflammatory 
bowel disease (IBD).
METHODS: Thirty ulcerative colitis (UC) and nine 
Crohn’s disease patients, and 20 control subjects were 
enrolled in this prospective study. Detailed clinical infor-
mation was obtained. Extent and activity of the bowel 
disease were established endoscopically. Each patient 
underwent pulmonary function tests and high-resolution 
computed tomography (HRCT). Blood samples for mea-
surement of C-reactive protein (CRP), erythrocyte sedi-
mentation rate (ESR), angiotensin converting enzyme 
and total IgE were delivered by the patients.
RESULTS: Ten (25.6%) patients had respiratory symp-
toms. A pulmonary function abnormality was present in 
22 of 39 patients. Among all patients, the most prevalent 
abnormalities in lung functions were a decrease in forced 
expiratory volume in 1 s (FEV1), FEV1/forced vital capaci-
ty (FVC), forced expiratory flow (FEF) 25%-75%, transfer 
coefficient for carbon monoxide (DLCO), DLCO/alveolar 
volume. Increased respiratory symptoms score was asso-
ciated with high endoscopic activity index in UC patients. 
Endoscopic and clinical activities in UC patients were 
correlated with FEV1, FEV1/FVC, and FEF 25%-75%. 
Smoking status, duration of disease and medication were 
not correlated with pulmonary physiological test results, 
HRCT abnormalities, clinical/endoscopic disease activity, 
CRP, ESR or total IgE level or body mass index.
CONCLUSION: It is important that respiratory mani-
festations are recognized and treated early in IBD. 
Otherwise, they can lead to destructive and irreversible 
changes in the airway wall.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic inflam-
matory disease that commonly involves the gastrointes-
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tinal tract, and it is of  unknown etiology. Crohn’s disease 
(CD) and ulcerative colitis (UC) are the two main forms 
of  chronic IBD. Extraintestinal manifestations are very 
common: dermatological manifestations, erythema no-
dosum and pyoderma gangrenosum; ocular manifesta-
tions, uveitis and episcleritis; hepatobiliary manifestations, 
primary sclerosing cholangitis and autoimmune hepatitis; 
musculoskeletal manifestations, peripheral arthritis and 
axial arthropathy[1]. In contrast, pulmonary involvement 
is rare. A relationship between pulmonary disease and 
IBD was suggested 40 years ago. Respiratory involve-
ment in IBD is disclosed with some pathophysiological 
mechanisms: both the colonic and respiratory epithelia 
share embryonic origin from the primitive foregut, and 
both types of  epithelial cells include goblet cells and sub-
mucosal glands; and the lungs and gastrointestinal tract 
contain submucosal lymphoid tissue and play crucial roles 
in host mucosal defense. The similarity in the mucosal im-
mune system causes the same pathogenetic changes. The 
aberrations in both innate and acquired immunity that are 
involved in the pathogenesis of  IBD are complex and still 
incompletely understood[2]. The patterns of  involvement 
in IBD are[2,3]: (1) upper airway: glottic/subglottic stenosis, 
tracheal inflammation and stenosis; (2) bronchi: chronic 
bronchitis, bronchiectasis, and chronic bronchial suppura-
tion; (3) small airways: bronchiolitis obliterans, bronchi-
olitis, and diffuse pan-bronchiolitis; (4) lung parenchyma: 
bronchiolitis obliterans-organizing pneumonia, nonspe-
cific interstitial pneumonia, granulomatous interstitial lung 
disease, desquamative interstitial pneumonitis, pulmonary 
infiltrates and eosinophilia, and sterile necrobiotic nodules; 
(5) sarcoidosis, α1 antitrypsin deficiency; (6) pulmonary 
vascular disease; Wegener’s granulomatosis, Churg-Strauss 
syndrome, microscopic polyangiitis, and pulmonary vascu-
litis; (7) venous thromboembolism; and (8) serositis: pleu-
ral and pericardial manifestations.
The aim of  present study was to evaluate pulmonary 
involvement in IBD. For this, we examined frequency of  
respiratory symptoms, pulmonary function tests, bronchi-
al hyperreactivity, high-resolution computed tomography 
(HRCT), serum angiotensin-converting enzyme (ACE), 
C-reactive protein (CRP) level and erythrocyte sedimenta-
tion rate (ESR).
MATERIALS AND METHODS
During a 2-year period from January 2007 to December 
2009, 39 consecutive patients with the diagnosis of  IBD, 
who were seen in a gastroenterology clinic, were referred 
to our outpatient clinic. Subjects with the following char-
acteristics were included: age ≥ 18 years old, CD and UC 
with endoscopic examination performed in a week.
Subjects with the following characteristics were ex-
cluded: lack of  compliance in performing lung function 
tests, age < 18 years old, history of  previous lung disease, 
history of  atopy or familial atopy, peripheral eosinophilia, 
and obesity [body mass index (BMI) > 30 kg/m2].
Thirty UC and nine CD patients were enrolled in 
this prospective study. Age- and sex-matched normal 
controls (20 subjects) were recruited from healthy volun-
teers. The detailed anamnesis of  the subjects (age, sex, 
cigarette pack/years, family history, occupational history) 
was gathered. Duration of  disease from the date of  first 
endoscopic diagnosis and maximal extent of  endoscopic 
diagnosis were recorded. The extent of  the bowel disease 
was defined as pancolitis when the entire colon was in-
volved; left-side colitis when the bowel from the hepatic 
flexure to the rectum was involved; and distal colitis when 
the sigmoid colon and rectum were involved. Patients 
with CD were classified with colon involvement, small 
bowel involvement, or ileocecal involvement. In patients 
with UC, the clinical activity of  the disease was assessed 
using the Truelove score[4]: mild was considered to be in 
remission, and patients with moderate and severe indices 
had active disease. Endoscopic activity was assessed by 
videocolonoscopy (Fujinon EC 450/WL, Tokyo, Japan). 
All colonoscopic examinations were performed by an 
experienced investigator. The Rachmilewitz endoscopic 
activity index for UC was used to assess disease activ-
ity[5]. CD activity was assessed on the basis of  clinical and 
endoscopic features[6]. Smoking habit was also recorded, 
however, most of  our patients were nonsmokers or for-
mer smokers. Symptoms of  cough, sputum, wheezing 
and breathlessness were scored out of  a maximum of  2: 
0 = no symptoms; 1 = intermittent symptoms; and 2 = 
regular symptoms. The total symptom score (maximum 
of  8) for each patient was derived from the sum of  the 
individual symptom scores. A total symptom score of  ≥ 
3 points was assessed as “respiratory symptom is present” 
or “symptomatic”[7]. Blood samples for measurement of  
CRP, ESR, ACE and total IgE were delivered by the pa-
tients prior to endoscopy. 
Pulmonary function testing
Each patient underwent standard pulmonary function 
tests for forced expiratory volume in 1 s (FEV1), vital 
capacity, forced vital capacity (FVC), and transfer coeffi-
cient for carbon monoxide (DLCO) measured by means 
of  the single-breath test. Account was also taken of  the 
hemoglobin value when calculating the DLCO. The re-
sults were compared with those of  age- and sex-matched 
controls and expressed as a percentage of  predicted val-
ues. Pulmonary function test indices were measured with 
a Sensormedics V max 229 (Sensormedics, Yonda Linda, 
CA, USA) series flow-sensitive spirometer. The limitation 
of  our study was that lung volumes could not be mea-
sured. Bronchial hyperresponsiveness (BHR) (PD20, dose 
of  methacholine that caused a 20% fall in FEV1) was 
measured in the morning with the methacholine chal-
lenge test using the dosimeter method according to ERS 
task force in all IBD patients[8]. In patients with high IgE 
level, the existence of  an atopic state was evaluated by 
skin prick test using common allergen extracts (grass, tree 
and weed pollens; house dust mites; molds; cat and dog 
extracts), and reactions at least 3 mm greater then nega-
tive control test were regarded as positive (Stallergenes, 
Antony cedex, France). Histamine was used as a positive 
control.
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HRCT
All CT scans were obtained with a scanner (Siemens So-
matom Emotion, Germany). Images were acquired during 
inspiration. CT scans were evaluated by an independent 
investigator who was blinded to the results of  the pul-
monary function tests and clinical data. The individual 
features evaluated included the following: bronchiectasis, 
bronchial wall thickening, ground-glass opacification, em-
physema and cysts.
Ethical considerations
Informed consent was obtained from all patients and 
control subjects and the study was approved by the local 
ethical committee.
RESULTS
Patient description
The characteristics of  the control group and the 39 pa-
tients with UC and CD are shown in Table 1. Twenty-
three male and 16 female (59%, 41%) patients, as well 
as 20 healthy controls, with mean ages of  44.28 ± 12.85 
years and 39.50 ± 12.47 years, respectively, were recruited 
to the study. The mean duration of  disease was 39.07 ± 
29.38 mo. Thirty individuals were never smokers, five were 
ex-smokers and four were smokers. Control patients were 
nonsmokers. None of  our patients had an occupational 
history or family history of  respiratory disease and atopy. 
Fifteen (50%) UC and four (44.4%) CD patients had clini-
cally active bowel disease at the time of  the study. Of  the 
39 patients, 33 were receiving sulfasalazine, one azathio-
prine, and five sulfasalazine plus azathioprine. None of  
the patients had extraintestinal manifestations other than 
pulmonary involvement. 
Twenty-five (64.10%) patients had HRCT abnormali-
ties (Table 2). Ten (25.6%) patients had respiratory symp-
toms. In 16 (41%) patients, CRP level was elevated, and in 
26 (66.7%), ESR was increased. Four (10.3%) patients had 
high levels of  total IgE, and in these patients, skin prick 
tests were negative, and in one patient, weak BHR was 
observed. 
 
Pulmonary function tests
Three (7.69%) patients had obstructive dysfunction and 
small airway obstruction was reported in 17 (43.58%). 
Two patients (5.12%) had restrictive dysfunction. When 
comparing all IBD patients with controls, we found statisti-
cally significant differences for FEV1, FEV1/FVC, FEF 
25%-75%, DLCO and DLCO/alveolar volume (VA) (P < 
0.05) (Table 3). 
Correlation between pulmonary function parameters, 
clinical characteristics and HRCT features
The correlation of  pulmonary function and endoscopic 
and clinical disease activity is shown in Tables 4 and 5. 
The most prevalent abnormality was a decrease in FEF 
25%-75% in patients with CD and endoscopically and 
clinically active UC. The impairment in FEV1 and FEV1/
FVC was significant and more pronounced in patients with 
active UC vs controls. In 10 (33.3%) patients with UC, the 
endoscopic activity index was high and correlated signifi-
cantly with pulmonary symptom scores (P < 0.05). There 
was no significant correlation between smoking status and 
pulmonary physiological test results, HRCT abnormalities 
or clinical/endoscopic disease activity. Also, no relation-
ship was found between disease activity and HRCT abnor-
malities, respiratory symptoms, CRP, total IgE level, ESR 
or BMI. There was no relationship between duration of  
disease and pulmonary physiological test results, HRCT 
abnormalities, CRP, total IgE level or ESR. There was no 
correlation between BMI and pulmonary function.
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Table 1  Characteristics of the control and patient groups with 
inflammatory bowel disease
UC CD Controls
n 30 9 20
Sex (M/F) 22/8 1/8 10/10
Mean age (yr) 43 ± 3 46 ± 2 39.50 ± 12.47
Smoking (smoker/never/
ex-smoker)
4/22/4 - -
Duration and range of bowel 
disease (yr) (mean ± SD)
3 ± 0.5 (0-9) 3 ± 0.5 (0.5-4)
Respiratory symptom 
(present/absent)
  9/21 1/8 0/20
Disease activity (active/
remission)
14/16 5/4
UC: Ulcerative colitis; CD: Crohn’s disease.
Table 2  Findings on high-resolution computed tomography in 
patients with inflammatory bowel disease
Findings on HRCT n
Normal 14
Peribronchial thickness 15
Bronchiectasis   2
Ground-glass opacity   8
Emphysema   9
Air cysts   1
Reticulonodular opacity   1
HRCT: High-resolution computed tomography.
Table 3  Correlations of pulmonary function tests with inflam-
matory bowel disease and controls
UC (n  = 30) CD (n  = 9) Controls (n  = 20)
FEV1    86.87 ± 15.09a   85.89 ± 13.75   95.75 ± 11.56
FVC   88.37 ± 15.80 93.22 ± 8.90   96.40 ± 10.00
FEV1/FVC  79.67 ± 8.98a   78.56 ± 11.11 84.15 ± 4.21
FEF 25%-75%   73.93 ± 21.38    64.89 ± 21.23a   85.00 ± 11.85
DLCO     96.43 ± 12.84a    90.67 ± 19.88a   103.5 ± 11.90
DLCO/VA 104.83 ± 16.99    93.00 ± 17.85a 112.95 ± 10.22
aP < 0.05 vs control group statistically significant. UC: Ulcerative colitis; CD: 
Crohn’s disease; FEV1: Forced expiratory volume in 1 s; FVC: Forced vital 
capacity; FEF: Forced expiratory flow; DLCO: Transfer coefficient for carbon 
monoxide; VA: Alveolar volume.
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DISCUSSION
Extraintestinal manifestations of  IBD are increasing in 
developed countries. In 1976, Kraft et al[9] described six 
patients in whom chronic bronchial suppuration had ap-
peared between 3 and 13 years after the onset of  IBD. 
Since then, all respiratory complaints in IBD patients that 
cannot be explained by other causes have been defined as 
pulmonary manifestations of  the disease. Furthermore, 
reports of  pulmonary manifestations of  the disease are 
increasingly present in the literature. In our patient group, 
among all patients, the most prevalent abnormalities in 
lung functions were a decrease in FEV1, FEV1/FVC, 
FEF 25%-75%, DLCO, and DLCO/VA. Increased re-
spiratory symptom score was associated with high endo-
scopic activity index in UC patients. The most prevalent 
abnormality was a decrease in FEF 25%-75% in patients 
with CD and endoscopically and clinically active UC. The 
impairment in FEV1 and FEV1/FVC was significant and 
more pronounced in patients with active UC compared 
with the controls.
Godet et al[10] have studied patients with UC, and 
pulmonary function test abnormalities were found in 
55%, 15/66 subjects had an obstructive pattern, 19 had 
abnormal diffusion, one had a restrictive pattern, and five 
had both an obstructive pattern and abnormal diffusion; 
these alterations could not be predicted by current or past 
smoking status, family history of  respiratory disease, oc-
cupational history or current medication use. In our study, 
3/39 (7.69%) patients had obstructive dysfunction, two 
(5.12%) had restrictive dysfunction, and five (12.8%) had 
abnormal diffusion. These results were not correlated 
with smoking status. None of  our patients had a family or 
occupational history of  respiratory disease.
The influence of  disease activity was studied. In a re-
cent study with UC patients, small airway obstruction (as 
demonstrated by diminished FEF 25%-75%) was report-
ed in the 15 patients (57.6%), restrictive dysfunction in 
eight (30.7%) and obstructive dysfunction in three (11.5%), 
and the impairment in pulmonary function tests was 
significant and more pronounced in patients with active 
UC compared with the controls[11]. In our study, the most 
prevalent abnormality was a decrease in FEF 25%-75%, 
and FEV1/FVC and FEF 25%-75% were significantly 
lower in patients with active UC. In 10 (33.3%) patients 
with UC, the endoscopic activity index was high and cor-
related significantly with pulmonary symptom scores (P < 
0.05). These findings suggest a direct pathogenic link with 
IBD. Tzanakis et al[12] have found small airway dysfunction 
in patients with CD and UC despite their normal baseline 
spirometric values, and there was no difference between 
active and nonactive disease. 
Chest radiography is often normal in patients with re-
spiratory symptoms and IBD. Bronchiectasis is the classic 
pulmonary manifestation of  IBD, and is noted in 66% of  
cases of  IBD that involve the large airways[2]. Mahadeva 
et al[7] have found bronchiectasis in 13 of  17 patients with 
IBD, in whom sputum production was present in 10. In 
contrast, bronchiectasis was identified in only two patients 
in the present study. In our study, the most frequent find-
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Table 4  Correlation of pulmonary function tests between endoscopically and clinically active Crohn’s disease with controls
Endoscopically 
active (n  = 5) inactive(n  = 4)
Clinically 
active (n  = 4) inactive (n  = 5)
Control (n  = 20)
FEV1        82 ± 12.28 90.75 ± 7.04   81.25 ± 19.50 89.60 ± 7.37   95.75 ± 11.56
FVC 91.20 ± 7.33   95.75 ± 11.15 92.25 ± 7.68   94.00 ± 10.61   96.40 ± 10.00
FEV1/FVC   75.80 ± 14.60      82 ± 4.08   74.25 ± 16.38      82 ± 3.54 84.15 ± 4.21
FEF 25%-75%   61.80 ± 28.84 68.75 ± 7.54   58.50 ± 32.07      70 ± 7.52           85 ± 11.85a,c
DLCO   91.20 ± 15.83        90 ± 26.81      103 ± 13.64   80.80 ± 19.42    103.5 ± 11.90c
DLCO/VA   95.40 ± 20.38        90 ± 16.55 102.25 ± 16.15   85.60 ± 16.95    112.95 ± 10.22a,c
aP < 0.05 comparison between active and control groups statistically significant; cP < 0.05 comparison between inactive and control groups statistically 
significant. FEV1: Forced expiratory volume in 1 s; FVC: Forced vital capacity; FEF: Forced expiratory flow; DLCO: Transfer coefficient for carbon monoxide; 
VA: Alveolar volume.
Table 5  Correlation of pulmonary function tests between endoscopically and clinically active ulcerative colitis with controls
Clinically 
active (n  = 15) inactive (n  = 15)
Endoscopically 
active (n  = 20) inactive (n  = 10)
Control (n  = 20)
FEV1   86.53 ± 13.15 87.20 ± 17.28   78.10 ± 19.58   91.25 ± 10.26c    95.75 ± 11.56a
FVC   91.60 ± 14.07 85.13 ± 17.22   86.70 ± 16.49  89.20 ± 15.81   96.40 ± 10.00
FEV1/FVC 78.07 ± 6.22 81.27 ± 11.08   72.70 ± 10.95 83.15 ± 5.28c   84.15 ± 4.21a
FEF 25%-75%   67.73 ± 19.00  80.13 ± 22.43c   53.80 ± 22.30        84 ± 11.93c           85 ± 11.85a,e
DLCO   97.93 ± 12.88 94.93 ± 13.07        96 ± 13.42  96.65 ± 12.89    103.5 ± 11.90e
DLCO/VA 107.67 ± 14.25    102 ± 19.44 106.50 ± 17.28     104 ± 17.24  112.95 ± 10.22e
aP < 0.05 comparison between active and control groups statistically significant; cP < 0.05 comparison between active and inactive groups statistically 
significant; eP < 0.05 comparison between inactive and control groups statistically significant. FEV1: Forced expiratory volume in 1 s; FVC: Forced vital 
capacity; FEF: Forced expiratory flow; DLCO: Transfer coefficient for carbon monoxide; VA: Alveolar volume.
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ing on HRCT was peribronchial thickness. The most com-
mon respiratory association of  IBD is inflammation of  
the airways. Biopsy shows either severe nonspecific chron-
ic inflammation or non-caseating tuberculoid granulomas. 
These appearances have been associated with those in the 
bowel, and it is possible that the gut and the lung are both 
affected because they share common antigens[13]. This in-
flammation is perceived on HRCT as an increase in bron-
chial wall thickness or an increase in diameter of  pulmo-
nary artery branches. In these patients, bronchial dilatation 
is commonly present and results from traction by fibrous 
tissue on the bronchial walls and results in bronchiecta-
sis[14]. Consequently, peribronchial thickness might reflect 
inflammation, which usually responds well to steroids[15]. 
In this way, bronchiectasis can be prevented. This finding 
suggests a direct pathogenic link to IBD as well.
The expiratory HRCT seems to be a limitation in our 
study and air trapping could have been underestimated. 
In our series, nine patients had upper lobe emphysema, 
which was probably related to smoking but there was no 
significant correlation between smoking status and pul-
monary physiological test results, HRCT abnormalities or 
clinical/endoscopic disease activity.
It is important to consider whether therapy with sul-
fasalazine or mesalazine could have been responsible for 
the pulmonary changes. The most common abnormality 
described in association with sulfasalazine therapy is up-
per lobe peripheral opacity, although lower lobe opacity, 
eosinophilic pneumonia, interstitial pneumonitis, bron-
chiolitis obliterans organizing pneumonia and cavitating 
nodules have also been reported[16,17]. None of  our pa-
tients had peripheral blood eosinophilia, which is usually 
present in lung disease caused by sulfasalazine.
Kuzela et al[18] have identified a high incidence of  pul-
monary function abnormalities (suspicious of  interstitial 
lung disorder) in patients with IBD, despite the lack of  
radiological abnormalities; 56.7% of  patients with UC and 
57.7% of  those with CD had reduced lung transfer factor. 
Tzanakis et al[12] have shown that DLCO is significantly 
lower among IBD patients with active gastrointestinal dis-
ease than those in remission. Marvisi et al[19] have studied 
32 patients with UC and found a mild reduction in DLCO 
and FEF 25%-75%, and the incidence was higher in pa-
tients with active disease despite the lack of  radiological 
alterations and pulmonary symptoms. Also, significant 
differences in mean FVC, FEV1, total lung capacity and 
FEV1\FVC values were found between patients with 
active and inactive UC. In our study, DLCO and DLCO/
VA were significantly lower among IBD patients, but not 
correlated with disease activity. 
Douglas et al[20] have studied 44 IBD patients and 
found that 48% had unspecified respiratory symptoms. 
Songür et al[21] have found that 16 of  36 IBD patients (44%) 
in a gastroenterology clinic had symptoms of  wheezing, 
cough, sputum production, or breathlessness. In our study, 
25.6% of  39 IBD patients had respiratory symptoms.
The true prevalence of  airway inflammation and re-
spiratory and atopic symptoms in IBD remains obscure. 
Ceyhan et al[22] have studied 30 consecutive IBD subjects; 
allergic symptoms were seen in 14 IBD patients, respira-
tory symptoms were found in 15, asthma and antiasth-
matic drug treatment were noted in three, and BHR was 
determined in four. They have concluded that allergic 
symptoms, respiratory symptoms, abnormal lung func-
tion tests and skin prick test positivity are more common 
among IBD patients in comparison with controls, and 
airway dysfunction is accompanied by atopy. Louis et al[23] 
have shown no correlation between BHR and airway in-
flammation in IBD patients, in contrast to asthma. In our 
study, we excluded subjects with atopy and a familial his-
tory of  atopy, subjects with peripheral eosinophilia. Four 
(10.3%) patients had high levels of  total IgE, and in these 
patients, skin prick tests were negative and in one patient, 
weak BHR was observed.
Nutritional status has been shown to have a significant 
influence on the overall pulmonary function in patients 
with IBD. Christie and Hill have demonstrated a 35% 
loss of  body protein stores and associated 40% physi-
ological impairment (FEV1, FVC and maximal voluntary 
ventilation) in patients with acute exacerbations of  CD, 
compared to controls. There was a significant immediate 
and delayed improvement in these parameters after 2 wk 
nutritional supplementation, and further improvement 
on restoration of  body proteins during convalescence[24]. 
Similarly, BMI has been examined as an index of  nutri-
tional status in patients with UC and in controls, and a 
significant positive correlation has been found between 
BMI and pulmonary function[10]. In our study, 19 patients 
were overweight (BMI: 25-29.9 kg/m2), and there was no 
correlation between BMI and pulmonary function. 
In conclusion, both the colonic and respiratory epi-
thelia share embryonic origin from the primitive foregut. 
The inflammatory lesions seen beneath the bronchial epi-
thelium are similar to those observed beneath the colonic 
epithelium in IBD. This means that there is inflammation 
that can be detected early by HRCT and pulmonary func-
tion tests. Although most patients have subclinical disease, 
the pulmonologist must be aware of  the multiple potential 
pulmonary manifestations that can occur in a patient with 
IBD. Otherwise, they tend to generate persistent and an-
noying symptoms, and can lead to destructive and irrevers-
ible changes in the airway wall, or the “end-stage lung”[3].
COMMENTS
Background
Crohn’s disease (CD) and ulcerative colitis (UC) are the two main forms of 
chronic inflammatory bowel disease (IBD), with unknown etiology. Extraintesti-
nal manifestations such as dermatological, ocular, hepatobiliary and musculo-
skeletal diseases are very common. In contrast, pulmonary involvement is rare. 
Research frontiers
Respiratory involvement in IBD is seen with some pathophysiological mecha-
nisms: both the colonic and respiratory epithelia share embryonic origin from 
the primitive foregut, both types of epithelial cells include goblet cells and 
submucosal glands, and both the lungs and gastrointestinal tract contain sub-
mucosal lymphoid tissue and play crucial roles in host mucosal defense. The 
similarity in the mucosal immune system causes similar pathogenic changes. 
The aberrations in both innate and acquired immunity that are involved in the 
pathogenesis of IBD are complex and still incompletely understood. In this 
study, pulmonary involvement in IBD was evaluated.
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Innovations and breakthroughs
The most prevalent abnormalities in lung functions are a decrease in forced 
expiratory volume in 1 s (FEV1), FEV1/forced vital capacity, forced expiratory 
flow 25%-75%, transfer coefficient for carbon monoxide (DLCO), DLCO/alveolar 
volume. The most frequent finding on high-resolution computed tomography, un-
like previous studies, was peribronchial thickness. The most common respiratory 
association of IBD is inflammation of the airways. Biopsy shows either severe 
nonspecific chronic inflammation or non-caseating tuberculoid granulomas. These 
appearances are associated with those in the bowel, and it is possible that the gut 
and the lung are both affected because they share common antigens. This inflam-
mation is perceived on high-resolution computed tomography as an increase in 
bronchial wall thickness or an increase in diameter of pulmonary artery branches. 
In these patients, bronchial dilatation is commonly present and results from 
traction by fibrous tissue on the bronchial walls, which results in bronchiectasis. 
Consequently, peribronchial thickness might reflect inflammation, which usually 
responds well to steroids. In this way, bronchiectasis can be prevented. 
Applications
Various pulmonary manifestations can occur in IBD. It is important that respiratory 
manifestations are recognized and treated early. Otherwise, they might lead to 
destructive and irreversible changes in the airway wall, or the “end-stage lung”.
Peer review
This is a very interesting study and gives us further insight into a disease that may 
manifest in various systems. Pulmonary disease in IBD has not been extensively 
studied because the problem is often treated only by gastroenterologists. This is 
a timely study and could lead to further studies that will help us understand more 
about this disease. 
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